Cancer reports最新文献

{"title":"Outcome of Surgical Treatment for Metastatic Bone Disease of the Forearm","authors":"Jennifer Sebghati,&nbsp;Panagiotis Tsagkozis","doi":"10.1002/cnr2.70208","DOIUrl":"https://doi.org/10.1002/cnr2.70208","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Metastatic bone disease and pathological fractures in the long bones of the forearm are rare. The methods and outcomes of surgical treatment for these fractures have not been adequately described.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To analyze the outcome of surgery for pathological fractures of the forearm.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Retrospective study of 30 complete and impending pathological fractures (28 consecutive patients) in the forearm, operated on in a single tertiary center between 1986 and 2020. The most common malignancy was hematological disease (multiple myeloma and lymphoma). Most fractures (<i>n</i> = 19) were managed with plate and screw reconstruction. In some cases, simple curettage or segmental resections of the metastasis were performed. Local complications were noted in six operations, the most common one being tumor relapse seen in three patients. Most patients had good outcomes regarding restoration of function and pain relief. There were no secondary surgeries in segmental resection, and the function was near normal.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Surgical reconstruction of metastases in the long bones of the forearm usually results in a good functional outcome with an acceptable complication rate. Plate osteosynthesis is often indicated. Segmental excision can be reserved for dispensable parts of the ulna and radius, with excellent results.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70208","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143865951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Cost-Effectiveness of a Multi-Target Stool DNA-Based Screening (COLOTECT), FIT, Colonoscopy and No Screening for Colorectal Cancer","authors":"Junjie Huang,&nbsp;Mingtao Chen,&nbsp;Victor C. W. Chan,&nbsp;Xianjing Liu,&nbsp;Chaoying Zhong,&nbsp;Jianli Lin,&nbsp;Junjie Hang,&nbsp;Claire Chenwen Zhong,&nbsp;Jinqiu Yuan,&nbsp;Martin C. S. Wong","doi":"10.1002/cnr2.70176","DOIUrl":"https://doi.org/10.1002/cnr2.70176","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Around 1.9 million new cases and 1 million deaths worldwide were attributed to colorectal cancer (CRC) in 2020.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The aims of this study are to assess the cost-effectiveness of a multi-target stool DNA-based screening strategy, COLOTECT, compared to faecal immunochemical tests (FIT), colonoscopy, and no screening in the Asian population to inform more choices for policymakers in colorectal cancer screening.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method and Results</h3>\u0000 \u0000 <p>We assume that 100,000 persons aged 50 undergo annual FIT, annual COLOTECT multi-target testing, or colonoscopies every 10 years until age 75. The data used in this study was retrieved from different sources including the Hong Kong Cancer Registry and previously published studies on the population aged 50 to 75 years old between 2010 and 2023. This study accessed the most cost-effective screening strategy available. If a positive result of FIT or COLOTECT were observed, the participants would undergo a colonoscopy. The participants who used the colonoscopy as the main screening method conducted colonoscopies every 3 years. The Markov models were utilized to compare the outcomes from different strategies including life-years saved, years of life lost, and incremental cost-effectiveness ratio (primary outcome). The highest ICER was observed in colonoscopy (USD 160808), followed by FIT (USD 108952), and COLOTECT (USD 82206). A higher detection rate of CRC (COLOTECT: 39.3% vs. FIT: 4.5%), more CRC cases prevented (1272 vs. 146), and life-years saved (2295 vs. 337) were observed in the COLOTECT strategy than in FIT. Additionally, a lower total cost per life-year saved of COLOTECT (USD 180097) was observed than colonoscopy (USD 238356), which identified the more affordable and cost-saving COLOTECT strategy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study highlighted the better performance of COLOTECT than FIT in detecting CRC. Additionally, given its lower cost and higher acceptance, the COLOTECT strategy might be more cost-effective than colonoscopy for massive CRC screening.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70176","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Cancer Metastasis: From Mechanisms to Treatments and Beyond","authors":"Mukul S. Godbole,&nbsp;Amruta Naik","doi":"10.1002/cnr2.70201","DOIUrl":"https://doi.org/10.1002/cnr2.70201","url":null,"abstract":"&lt;p&gt;Metastasis is an important attribute of cancer cells. If and when the primary tumor microenvironment becomes less conducive for growth and sustenance, metastatic growth allows cancer cells to explore potentially more conducive environments for survival and territorial expansion, instead of perishing at the original site. Cancer cells utilize multiple cellular mechanisms for processes such as detaching from the initial tumor site (migration and invasion), intravasation (crossing the endothelial barrier), circulation (movement through blood and/or lymph), extravasation (exit from circulation into a secondary tissue), and colonization (establishment of micro-metastases). These processes are further supported by angiogenesis (development of new blood vessels), immune evasion (overcoming immune regulation), modulation of primary and secondary tissue microenvironments (modulation of tumor-infiltrating immune cell activity, suppression of antitumor effects, etc.), secretion of tissue growth factors supporting metastases, and evasion of cell death. Moreover, the smooth transitions and interlinks between each of these processes adds to the complexity of metastasis and, hence, makes it difficult and crucial to target the processes that allow systemic spread of cancer cells. The “Cancer Metastasis: Mechanisms and Treatment” special issue primarily focuses on discussing the various mechanisms that drive metastasis of cancer cells to regional or distant organs and explores the strategies to target these metastatic processes, ultimately aiming to improve patient outcomes. We believe that the research and review articles published as part of the special issue would collectively aid in improving our current understanding and allow more critical research in the field. Here, we provide glimpses of all articles published in the special issue and encourage the readers to further dwell into the intricacies discussed in each of the articles.&lt;/p&gt;&lt;p&gt;Breast cancer, known for its high prevalence and tumor heterogeneity among women, frequently metastasizes to distant organs, such as the brain, lungs, liver, lymph nodes, and bones, leading to poor survival outcomes. Unfortunately, traditional treatments such as chemotherapy, radiotherapy, endocrine therapy, and immunotherapy show limited success in patients with metastatic breast cancer. A review article by Naik and Godbole offers a comprehensive discussion on the interesting, yet underexplored, roles of gut and breast microbiomes in influencing breast cancer metastasis, particularly to the bone [&lt;span&gt;1&lt;/span&gt;]. The article elaborates on the mechanisms by which microorganisms either promote or abrogate breast cancer metastasis, such as epithelial–mesenchymal transition, immune modulation in the bone microenvironment, enhanced cancer cell survival in circulation due to bacteria-induced altered cytoskeletal architecture, intratumoral persistence of bacteria in metastasizing cancer cells, altered steroid hormone metabolism","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70201","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography as a Predictor of Treatment Response to Neoadjuvant S-1 + Oxaliplatin Chemotherapy for Gastric Cancer","authors":"Naoki Urakawa,&nbsp;Shingo Kanaji,&nbsp;Ryuichiro Sawada,&nbsp;Yasufumi Koterazawa,&nbsp;Taro Ikeda,&nbsp;Hitoshi Harada,&nbsp;Hironobu Goto,&nbsp;Hiroshi Hasegawa,&nbsp;Kimihiro Yamashita,&nbsp;Takeru Matsuda,&nbsp;Yoshihiro Kakeji","doi":"10.1002/cnr2.70190","DOIUrl":"https://doi.org/10.1002/cnr2.70190","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Neoadjuvant chemotherapy is widely recognized as the established treatment for advanced gastric cancer. However, predicting its efficacy before surgery remains challenging.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The present study aimed to evaluate the effectiveness of 18F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) as a predictor of treatment response to the S-1+Oxaliplatin regimen (SOX).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Thirty patients who underwent gastrectomy following neoadjuvant SOX between January 2021 and July 2023 were included. Patients underwent FDG-PET pre- and postsurgery. The maximum standardized uptake value (SUVmax) from FDG-PET was examined in relation to histological tumor response and prognosis. SUVmax decreased significantly after chemotherapy in all patients (<i>p</i> &lt; 0.001), especially in those with Grade 1a, 2, and 3 tumors (<i>p &lt;</i> 0.05). SUV reduction increased stepwise with the histological response grade. Optimal cut-off values for the percentage decrease in SUVmax (ΔSUVmax) predictive of histologic efficacy were identified as 53% (area under curve 0.855, <i>p =</i> 0.0018) for Grade 1b or higher and 75% (area under curve 0.806, <i>p</i> = 0.0044) for Grade 2 or higher. Patients with ΔSUVmax &gt; 50% had improved recurrence-free survival (<i>p =</i> 0.027).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>FDG-PET may be useful as a predictor of treatment response in neoadjuvant SOX therapy for gastric cancer. The determination of the optimal ΔSUVmax value may enhance the precision of histological tumor response prediction.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70190","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunophenotypic Profiling of Acute Promyelocytic Leukemia: Insights From a Large Cohort","authors":"Supattra Kankhaw,&nbsp;Weerapat Owattanapanich,&nbsp;Orathai Promsuwicha,&nbsp;Thanyakan Thong-ou,&nbsp;Theera Ruchutrakool,&nbsp;Archrob Khuhapinant,&nbsp;Karan Paisooksantivatana,&nbsp;Smith Kungwankiattichai","doi":"10.1002/cnr2.70198","DOIUrl":"https://doi.org/10.1002/cnr2.70198","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Acute promyelocytic leukemia (APL) is a highly aggressive disease that requires early initial therapy. Rapid diagnosis by flow cytometry remains the mainstay of initial diagnosis. However, the complexity of its immunochemistry has led to diagnostic uncertainty.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>We comprehensively reviewed 2124 AML patients, with 170 classified as APL. In the univariate analysis, HLA-DR, CD34, CD56, CD11b, and CD11c were predominantly positive in the non-APL group compared to the APL group, while MPO and CD33 were significantly positive in the APL group. In the multivariate analysis, MPO was identified as a significantly higher positive marker in APL patients, while HLA-DR, CD34, and CD56 predicted non-APL patients. The typical immunophenotype of APL, including MPO+/HLA-DR-/CD34- and CD117+, provided a sensitivity of 51.4%, a specificity of 98.0%, a positive predictive value of 65.8%, and a negative predictive value of 96.5%. By utilizing the decision tree methodology, HLA-DR, MPO, and CD34 emerged as pivotal indicators for APL diagnosis within this model. Notably, HLA-DR took precedence, followed by MPO and CD34. Ultimately, a predictive equation for APL diagnosis was proposed to simplify the diagnosis of APL by flow cytometry using the positivity of HLA-DR, MPO, and CD34 as reference points.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study underscores the role of immunophenotyping as a rapid and complementary tool to molecular diagnostics, aiding in the preliminary identification of probable APL cases and facilitating timely initiation of therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70198","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143849066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tailored Therapeutic Approach in a Patient With Diffuse Large B-Cell Lymphoma With Meningeal Infiltration, Concurrent Classic Hodgkin Lymphoma, and Smoldering Multiple Myeloma: A Case Report","authors":"Giusy Ceparano,&nbsp;Daniele Lorenzini,&nbsp;Maurilio Ponzoni,&nbsp;Giorgia Levati,&nbsp;Davide Epifania,&nbsp;Vincenzo Marasco","doi":"10.1002/cnr2.70102","DOIUrl":"https://doi.org/10.1002/cnr2.70102","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Coexisting primary hematologic malignancies in untreated multiple myeloma (MM) are rare.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>A 69-year-old man with smoldering multiple myeloma (sMM) presented with lymphadenopathies and an intracranial mass. He was diagnosed with diffuse large B-cell lymphoma (DLBCL), classic Hodgkin lymphoma (cHL), and sMM. The patient received R-CHOP and R-ICE, followed by autologous stem cell transplantation, achieving complete remission of DLBCL and cHL, and very good partial remission of MM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case illustrates the complexity of managing multiple malignancies and the importance of a tailored therapeutic approach.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70102","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143830979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting Prognosis and Immunotherapy Response in Glioblastoma (GBM) With a 5-Gene CAF-Risk Signature","authors":"Haifeng He,&nbsp;Min Yan,&nbsp;Ke Ye,&nbsp;Rui Shi,&nbsp;Luqing Tong,&nbsp;Shengxiang Zhang,&nbsp;Yu Zhu,&nbsp;Renya Zhan","doi":"10.1002/cnr2.70158","DOIUrl":"https://doi.org/10.1002/cnr2.70158","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Cancer-associated fibroblasts (CAF) represent significant constituents within the extracellular matrix (ECM) across a range of cancers. Nevertheless, there exists a scarcity of direct proof concerning the function of CAF in glioblastoma (GBM).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Aims&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study endeavors to probe the participation of CAF in GBM by developing and validating a CAF-risk signature and exploring its correlation with immune infiltration and immunotherapy responsiveness.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods and Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To fulfill these objectives, mRNA expression profiles of GBM samples and their corresponding clinical data were retrieved from two databases. First, stromal CAF-associated genes were identified by weighted gene co-expression network analysis (WGCNA). This method constructs co-expression networks and pinpoints gene modules with similar expression patterns to detect relevant genes. Subsequently, a CAF-risk signature was established via univariate and LASSO Cox regression analyses. Thereafter, gene set enrichment analysis (GSEA) and single-sample gene set enrichment analysis (ssGSEA) were carried out to investigate the underlying molecular mechanisms. The immune status was evaluated with several R packages, and the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm was utilized to assess the response to immunotherapy. Validation was performed using single-cell RNA sequencing (scRNA) datasets, the Cancer Cell Line Encyclopedia (CCLE), and the Human Protein Atlas (HPA). Eventually, a 5-gene (ITGA5, MMP14, FN1, COL5A1, and COL6A1) prognostic CAF model was constructed. Notably, immune infiltration analysis demonstrated a significant correlation between Treg, Macrophage, and CAF risk scores. Moreover, TIDE analysis suggested a decreased responsiveness to immunotherapy in high CAF-risk patients. In addition, GSEA showed significant enrichment of the transforming growth factor alpha (TGF-α), inflammatory response, and epithelial–mesenchymal transition (EMT) pathways in this subgroup. Finally, the validation through scRNA, CCLE, and HPA datasets confirmed these findings.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The 5-gene CAF-risk signature exhibited accurate prognostic predictions and efficiently evaluated clinical immunotherapy responses among GBM patients. These results offer robust evidence regarding the implication of CAF in GBM and underscore the potential clinical value of personalized anti-CAF therapies in conjunction with immunotherapy.&lt;/p&gt;\u0000 &lt;/secti","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70158","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143827022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and Characterization of Differentially Expressed MicroRNAs in Benign Prostatic Hyperplasia","authors":"Lingmin Song,&nbsp;Xue Wang,&nbsp;Gang Wang,&nbsp;Liwei Zheng,&nbsp;Zhansong Zhou","doi":"10.1002/cnr2.70178","DOIUrl":"https://doi.org/10.1002/cnr2.70178","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The primary aim of this research is to identify and describe the distinct patterns of microRNAs (miRNAs) that are unusually expressed in benign prostatic hyperplasia (BPH) tissues compared to normal prostatic tissues.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>The investigation began with the collection of three samples each from normal prostatic and BPH tissues. These samples underwent miRNA microarray analysis using the Agilent platform. Following the preliminary screening, a larger sample set, comprising five normal prostatic tissues and 36 BPH tissues, was subjected to qRT-PCR to confirm the differential expression of the miRNAs initially identified.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The microarray analysis revealed that only miR-126-3p and miR-4672 exhibited an expression profile marked by both a fold change &gt; 1.5 and <i>p</i> &lt; 0.05, indicating significant downregulation in BPH tissues. MiR-145-3p and miR-143-3p also showed downregulation with fold changes greater than 1.5; however, these changes did not reach statistical significance as their p-values were above 0.05. Further attempts to validate these findings through qRT-PCR did not confirm any notable dysregulation among the four miRNAs studied; the variations in their expression levels between normal and BPH tissues did not achieve statistical significance, with p-values exceeding 0.1. From the data accrued, it can be inferred that the roles of miR-4672, miR-126-3p, miR-145-3p, and miR-143-3p in BPH development continue to be an unresolved mystery, and the need for further investigation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This preliminary investigation establishes a foundation for subsequent studies aimed at elucidating the regulatory mechanisms underlying BPH. However, these results highlight the need for further investigation employing a more extensive sample size and comprehensive clinical data to elucidate their potential roles in the pathogenesis of BPH.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70178","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143826893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions and Attitudes Toward Utilizing a Non-Invasive Biomarker for Colorectal Cancer Screening: A Qualitative Study","authors":"Choi Ying Chu,&nbsp;Junjie Huang,&nbsp;Jamie Jie Mei Liew,&nbsp;Apurva Sawhney,&nbsp;Xianjing Liu,&nbsp;Chaoying Zhong,&nbsp;Jianli Lin,&nbsp;Junjie Hang,&nbsp;Claire Chenwen Zhong,&nbsp;Jinqiu Yuan,&nbsp;Martin C. S. Wong","doi":"10.1002/cnr2.70140","DOIUrl":"https://doi.org/10.1002/cnr2.70140","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Colorectal cancer (CRC) screening, effective for early detection of CRC, was recently implemented by the Hong Kong government using the quantitative Fecal Immunochemical Test (FIT). However, consistently low participation rates and heavy reliance on colonoscopy for CRC screening has created a substantial burden on the healthcare system.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study examined the feasibility, acceptability, and satisfaction of utilizing the novel non-invasive biomarker test Colotect for early detection of CRC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>In-depth, qualitative telephone interviews were conducted with 16 participants (≥ 50 years old) who were eligible for the government CRC screening program. Participants were recruited via community health centres in Hong Kong between July and August 2022. The Consolidated Framework for Implementation Research (CFIR) was used to prepare the interview guide exploring the perceptions, attitudes, and barriers to using Colotect. The data collected was categorized into eight themes corresponding to the CFIR interventional characteristics domain, including intervention sources, evidence strength &amp; quality, relative advantage, adaptability, complexity, design quality and packaging, and cost.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Overall, participants reflected positive attitudes and perceptions toward Colotect use, along with identifying difficulties associated with its use. Modifications to test kits were proposed corresponding to the issues identified. In summary, this study demonstrated the feasibility and acceptability of using Colotect in CRC screening program. Future studies should examine the applicability, acceptability, efficiency, and cost-effectiveness of the test in real-world settings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70140","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143818421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"APOBEC3B Does Not Promote Tumor Progression in Tp53 Hemizygous Mice","authors":"Yoshihito Horisawa,&nbsp;Tadahiko Matsumoto,&nbsp;June Takeda,&nbsp;Yusuke Tashiro,&nbsp;Ryosuke Nomura,&nbsp;Suguru Takeuchi,&nbsp;Yugo Kawai,&nbsp;Yasuhiro Kazuma,&nbsp;Yoshinobu Konishi,&nbsp;Hiroyuki Yamazaki,&nbsp;Hiroyuki Matsui,&nbsp;Kotaro Shirakawa,&nbsp;Akifumi Takaori-Kondo","doi":"10.1002/cnr2.70189","DOIUrl":"https://doi.org/10.1002/cnr2.70189","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>DNA cytosine deaminase APOBEC3B (A3B) is one of the endogenous sources of somatic mutations in many types of human cancers and is associated with tumor progression rather than tumorigenesis. However, it remains uncertain whether APOBEC3B-induced mutations accelerate tumor progression or not. In this paper, we established a mouse model with A3B overexpression and investigated whether the introduction of A3B overexpression accelerates tumor development in <i>Tp53</i> hemizygous mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We established A3B transgenic mouse by microinjection and selected the mouse which has only one A3B transgene by genomic qPCR and southern blotting using the probe against the transgene. A3B expression was validated by qPCR, immunoblotting, immunohistochemistry and <i>in vitro</i> CDA assays using lysates of this transgenic mouse liver, spleen and bone marrow. We interbreed this transgenic mouse model with CAG-Cre and <i>Tp53</i> knockout mice and observed differences in tumor progression and survival between <i>Tp53</i> hemizygous mice and <i>Tp53</i> homozygous mice irrespective of A3B expression. Finally, comprehensive genomic mutation analysis was done using the developed tumors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We established A3B transgenic mouse which has only one transgene. A3B expression and its CDA activity were confirmed in liver cells and tumor tissues of mice overexpressing A3B. <i>Tp53</i> hemizygous mice developed osteosarcomas, spindle and pleomorphic sarcomas, and squamous cell carcinomas, however we did not observe any difference in tumor development between the mice with or without A3B expression. The tumor with A3B expression has more high-VAF mutations than the one without A3B, but these mutations are not APOBEC signature.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We developed a Cre inducible A3B transgenic mouse model bearing single copy of <i>A3B</i> gene. Although the introduction of A3B overexpression did not accelerate tumor development in <i>Tp53</i> hemizygous mice, our mouse model with A3B overexpression is well-validated and useful for further research.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70189","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143818420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}